UAE Cancer Diagnostics Market Size & Outlook, 2023-2030
UAE cancer diagnostics market, 2018-2030 (US$M)
Related Markets
UAE cancer diagnostics market highlights
- The UAE cancer diagnostics market generated a revenue of USD 397.9 million in 2023 and is expected to reach USD 609.1 million by 2030.
- The UAE market is expected to grow at a CAGR of 6.3% from 2024 to 2030.
- In terms of segment, consumables was the largest revenue generating product in 2023.
- Consumables is the most lucrative product segment registering the fastest growth during the forecast period.
Cancer diagnostics market data book summary
| Market revenue in 2023 | USD 397.9 million |
| Market revenue in 2030 | USD 609.1 million |
| Growth rate | 6.3% (CAGR from 2023 to 2030) |
| Largest segment | Consumables |
| Fastest growing segment | Consumables |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Services, Instruments, Consumables |
| Key market players worldwide | Abbott Laboratories, Roche Holding AG, GE HealthCare Technologies Inc Common Stock, Qiagen NV, Becton Dickinson & Co, Koninklijke Philips NV, Siemens Healthineers AG ADR, Hologic Inc, Thermo Fisher Scientific Inc, Illumina Inc |
Other key industry trends
- In terms of revenue, UAE accounted for 0.4% of the global cancer diagnostics market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Middle East & Africa, Saudi Arabia cancer diagnostics market is projected to lead the regional market in terms of revenue in 2030.
- UAE is the fastest growing regional market in Middle East & Africa and is projected to reach USD 609.1 million by 2030.
Consumables was the largest segment with a revenue share of 59.99% in 2023. Horizon Databook has segmented the UAE cancer diagnostics market based on services, instruments, consumables covering the revenue growth of each sub-segment from 2018 to 2030.
Several favorable strategic initiatives have been undertaken in the country. In April 2022, Viafet Genomics Laboratory collaborated with Euformatics to provide carrier screening and clinical diagnostics in the UAE. Similarly, in July 2022, G24 Healthcare expanded its clinical genetics offerings with the launch of 250 comprehensive testing panels with the shortest turnaround time.
The panels expanded the company’s offerings, enabling it to make personalized treatment options a reality in the UAE. Moreover, the UAE is one of the leading contributors to the cancer burden in the MEA. According to UAE National Cancer Registry in 2019, the country reported over 4,633 new cancer cases, of which 4,381 were malignant and 252 were in situ cases.
Thus, the high disease burden in the country is fueling the demand for new cancer testing laboratories with advanced diagnostics tests. In May 2020, a new liquid biopsy laboratory was established at the Thumbay Research Institute for Precision Medicine at the Gulf Medical University. This laboratory facilitated cancer diagnosis and management in the UAE.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cancer Diagnostics Market Scope
Cancer Diagnostics Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
UAE cancer diagnostics market size, by product, 2018-2030 (US$M)
UAE Cancer Diagnostics Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
